We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+48.92%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$7.15B
AUM Growth
+$1.69B
Cap. Flow
+$592M
Cap. Flow %
8.27%
Top 10 Hldgs %
50.83%
Holding
92
New
22
Increased
4
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$275M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$173M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$144M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$101M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$77.9M

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$134M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$109M
3
PCVX icon
Vaxcyte
PCVX
+$58.5M
4
VXRT
Vaxart
VXRT
+$51.3M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Financials 0.3%
3 Miscellaneous 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FVAM
76
DELISTED
5:01 Acquisition Corp
FVAM
$7.63M 0.11%
+750,000
New +$7.58M
VRDN icon
77
Viridian Therapeutics
VRDN
$2.47B
$7.43M 0.1%
+451,932
New +$6.81M
ELVN icon
78
Enliven Therapeutics
ELVN
$3.91B
$5.49M 0.08%
62,201
-234
-0.4% -$19.6K
PROF
79
Profound Medical
PROF
$208M
$3.95M 0.06%
+192,311
New +$3.54M
XFOR icon
80
X4 Pharmaceuticals
XFOR
$359M
$3.45M 0.05%
17,899
-751
-4% -$148K
CEREW
81
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.32M 0.02%
+233,333
New +$941K
OVID icon
82
Ovid Therapeutics
OVID
$529M
$658K 0.01%
285,000
– –
CLDX icon
83
Celldex Therapeutics
CLDX
$3.02B
– –
-353,072
Closed -$5.24M
EPIX
84
DELISTED
ESSA Pharma
EPIX
– –
-470,428
Closed -$3.25M
MCRB icon
85
Seres Therapeutics
MCRB
$46.2M
– –
-237,500
Closed -$134M
RLMD icon
86
Relmada Therapeutics
RLMD
$474M
– –
-781,290
Closed -$29.4M
VSTM icon
87
Verastem
VSTM
$665M
– –
-672,181
Closed -$9.76M
GRTX
88
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-825,118
Closed -$7.46M
FSDC
89
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-1,000,000
Closed -$11.2M
EIDX
90
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-2,163,271
Closed -$109M
PRVL
91
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-1,915,568
Closed -$19.5M
ARYBU
92
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
– –
-700,000
Closed -$7.7M
1 2 3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, RA Capital Management held 92 positions worth $7.15B, up 31% from $5.47B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management deployed $592M of net new capital in Q4 2020, opening 22 new positions and adding to 4 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,368,451 shares worth $224M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $58.5M trimmed.

  • RA Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 5,368,451 shares worth $224M.
  • RA Capital Management added most to Novavax in Q4 2020, an estimated $275M increase.
  • RA Capital Management's biggest Q4 2020 reduction was Vaxcyte, cutting an estimated $58.5M.
  • RA Capital Management fully exited Seres Therapeutics in Q4 2020, selling an estimated $134M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.15B portfolio in Q4 2020.
  • RA Capital Management opened 22 new positions and closed 10 in Q4 2020.
  • RA Capital Management's portfolio value rose 31% quarter-over-quarter to $7.15B.

Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.